Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 19, 2007

Akorn Licenses Cipla’s Injectable Organ Transplant Rejection Drug for U.S. Market

  • Akorn signed an exclusive drug development and supply agreement with Cipla for an injectable drug product for the prevention of organ transplant rejection. In June, Akorn announced an exclusive agreement for the oral dosage form of this drug product. The addition of the injectable format expands the breadth of Akorn's offerings for this indication.

    Under terms of the 10-year deal, Cipla will be responsible for the development, manufacturing, and supply of the drug product. Akorn will be responsible for the ANDA regulatory submission as well as marketing and distribution in the U.S. and Puerto Rico. Cipla will receive milestone fees for assistance with the ANDA development.

    Akorn will own the ANDA in the U.S. The drug will be purchased from Cipla on an exclusive basis. Akorn expects to launch the product in late 2009.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »